Nov 11, 2016, 04:00 ET Approval from the EC grants a centralized marketing authorization with unified labeling in the 28 countries that are members of the EU. Norway, Iceland and Liechtenstein, as members of the European Economic Area (EEA), will take corresponding decisions on…
Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent. The…
AUBURN, Ala. — An Alabama company is recalling a popular thyroid pill after testing confirmed the product had the potential to be “superpotent.” In a company announcement posted to the U.S. Food and Drug Administration website on Monday, Vitruvias Therapeutics…
Presented by: AJMC, Pharmacy Times & CancerNetwork At the American Academy of Ophthalmology's annual conference, Rona Z. Silkiss, MD, FACS, an oculoplastic surgeon and owner of Silkiss Eye Surgery, dived into how biologic therapies can be used to treat thyroid eye disease…
Ophthalmology Times Related to this article Trending on Eye Care Network - Ophthalmology Times CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA Murtaza K. Adam, MD, on pearls for the Yamane scleral-fixated…
The FDA record cites a “Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications” as the reason for recalling five lots of telmisartan and amlodipine tablets. Pharmaceutical company Viatris Inc. is recalling the medication. The concern…
Apothecary Pharma is recalling 22 vials of compounded tirzepatide and one NAD+ vial nationwide, citing a lack of assurance of sterility. A North Carolina outsourcing facility is pulling 22 vials of compounded tirzepatide injection from the market nationwide because it cannot assure…
The FDA classified the recall as Class II The FDA has announced that Apothecary Pharma is recalling 22 vials of injectable Tirzepatide distributed across the US after concerns were raised. Tirzepatide has surged in popularity for its weight loss benefits in…
Get the latest FDA updates on medication recalls, manufacturing violations, and quality concerns that could affect your prescriptions The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling…
A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide, produced and sold by Apothecary Pharma, has been recalled from sale in the US over sterility concerns. The compounding pharma company, based in Cary, North Carolina, is recalling…
Thyroid disease, from hypothyroidism to Graves' disease, adrenal and pituitary disorders and endocrinology news.
An article joins this feed when it matches these terms. Each one is also a search of its own.